论文部分内容阅读
为评价阿司匹林缓释片对高血压病或冠心病患者的心脑血管事件发生率的影响以及年龄、血压、性别、吸烟等高危因素的影响。由湖南省医院管理协会牵头 ,联合省心脑血管病防治网络内的娄底市中心医院、衡阳市中心医院和长沙市第一人民医院等 13家二甲和三甲医院进行了开放式多中心随机对照研究 ,完成临床研究病例 2430例 ,其中治疗组 12 6 4例 ,在给予降压或冠心病常规治疗的基础上 ,加用塞宁 (肠溶阿司匹林缓释片 ) 5 0mg/d～10 0mg/d ;对照组 116 6例 ,只给予常规治疗。结果发现 ,治疗组和对照组相比 ,事件总发生率及脑梗死、脑出血、心肌梗死等终点事件的发生率均具有明显的统计学差异 (P <0 .0 5或者P <0 .0 0 1)。治疗组发生心脑血管事件较对照组的相对危险度为 0 .34 1(0 .2 5 4～ 0 .46 0 ) ,其中发生脑梗死的相对危险度为 0 .379(0 .2 5 8～ 0 .5 5 9) ,发生脑出血的相对危险度为 0 .2 0 3(0 .10 6～ 0 .388) ,发生心肌梗死的相对危险度为 0 .335 (0 .10 7～ 1.0 5 1) ,而因心脑血管事件死亡的相对危险度为 0 .148(0 .0 5 2～ 0 .42 3)。此研究结果证实 ,给高危人群常规治疗的同时加用小剂量的阿司匹林缓释片可以显著降低脑卒中等心脑血管事件的发生率。研究结果还发现 ,年龄、血压、性别、吸烟及?
To evaluate the impact of aspirin sustained-release tablets on the incidence of cardiovascular and cerebrovascular events in patients with hypertension or coronary heart disease, as well as the impact of age, blood pressure, gender and smoking risk factors. Led by Hunan Provincial Hospital Management Association, Loudi Central Hospital, Hengyang Central Hospital and Changsha First People’s Hospital led by Hunan Provincial Hospital Management Association underwent an open, multi-center randomized controlled study Study completed 2430 cases of clinical studies, of which 1264 cases in the treatment group, given conventional treatment of antihypertensive or coronary heart disease, based on the addition of Cenine (enteric-coated aspirin sustained-release tablets) 50mg / d ~ 100mg / d; control group of 116 6 cases, only give conventional treatment. The results showed that compared with the control group, the incidence of end-point events and the incidence of end-points such as cerebral infarction, cerebral hemorrhage and myocardial infarction were significantly different between the treatment group and the control group (P <0.05 or P <0. 0 0 1). The relative risk of cardiovascular and cerebrovascular events in the treatment group compared with the control group was 0.341 (0.254 ~ 0.46 0), and the relative risk of developing cerebral infarction was 0.379 (0.258 ~ 0.559). The relative risk of developing cerebral hemorrhage was 0.203 (0.106 ~ 0.388), the relative risk of myocardial infarction was 0.335 (0.107 ~ 1.0 5 1). The relative risk of death from cardiovascular and cerebrovascular events was 0.148 (0.052-0.442). This study confirmed that routine treatment of high-risk groups with small doses of aspirin extended release tablets can significantly reduce the incidence of stroke and other cardiovascular and cerebrovascular events. The study also found that age, blood pressure, gender, smoking and?